Drug Interactions between Quzyttir and ritonavir
This report displays the potential drug interactions for the following 2 drugs:
- Quzyttir (cetirizine)
- ritonavir
Interactions between your drugs
cetirizine ritonavir
Applies to: Quzyttir (cetirizine) and ritonavir
MONITOR: Coadministration with ritonavir may increase the plasma concentrations of cetirizine. The exact mechanism is unknown but may involve ritonavir inhibition of the renal excretion of cetirizine. In 16 healthy volunteers, pretreatment with ritonavir (300 mg twice a day titrated to 600 mg twice a day, days 1 to 20) increased the steady-state area under the plasma concentration-time curve (AUC) and elimination half-life of cetirizine (10 mg orally once a day, days 15 to 20) by 42% and 53%, respectively, compared to administration of cetirizine alone. The apparent total body clearance of cetirizine was reduced by 29% with ritonavir. No serious drug-related adverse effects were reported in the study. Cetirizine did not significantly affect the pharmacokinetics of ritonavir.
MANAGEMENT: Pharmacologic effects of cetirizine may be increased during coadministration with ritonavir, particularly in the elderly and patients with renal impairment. Patients may experience increased somnolence and should be counseled to avoid activities requiring mental alertness until they know how these agents affect them. The same precaution may be applicable during therapy with levocetirizine, although clinical data are lacking.
References
- Peytavin G, Gautran C, Otoul C, et al. (2005) "Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers." Eur J Clin Pharmacol, 61, p. 267-73
Drug and food interactions
cetirizine food
Applies to: Quzyttir (cetirizine)
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
ritonavir food
Applies to: ritonavir
ADJUST DOSING INTERVAL: Administration with food may modestly affect the bioavailability of ritonavir from the various available formulations. When the oral solution was given under nonfasting conditions, peak ritonavir concentrations decreased 23% and the extent of absorption decreased 7% relative to fasting conditions. Dilution of the oral solution (within one hour of dosing) with 240 mL of chocolate milk or a nutritional supplement (Advera or Ensure) did not significantly affect the extent and rate of ritonavir absorption. When a single 100 mg dose of the tablet was administered with a high-fat meal (907 kcal; 52% fat, 15% protein, 33% carbohydrates), approximately 20% decreases in mean peak concentration (Cmax) and systemic exposure (AUC) were observed relative to administration after fasting. Similar decreases in Cmax and AUC were reported when the tablet was administered with a moderate-fat meal. In contrast, the extent of absorption of ritonavir from the soft gelatin capsule formulation was 13% higher when administered with a meal (615 KCal; 14.5% fat, 9% protein, and 76% carbohydrate) relative to fasting.
MANAGEMENT: Ritonavir should be taken with meals to enhance gastrointestinal tolerability.
References
- (2001) "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.